143 related articles for article (PubMed ID: 16539643)
1. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab.
Lehnhardt A; Mengel M; Pape L; Ehrich JH; Offner G; Strehlau J
Am J Transplant; 2006 Apr; 6(4):847-51. PubMed ID: 16539643
[TBL] [Abstract][Full Text] [Related]
2. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation.
Zarkhin V; Li L; Kambham N; Sigdel T; Salvatierra O; Sarwal MM
Am J Transplant; 2008 Dec; 8(12):2607-17. PubMed ID: 18808404
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in the treatment of acute cellular rejection of renal allograft with CD20-positive clusters in the infiltrate.
Vega J; Goecke H; Carrasco A; Escobar C; Escobar M; Espinosa R; Méndez G; de Los Ángeles Rodríguez M
Clin Exp Nephrol; 2011 Apr; 15(2):308-11. PubMed ID: 21152944
[TBL] [Abstract][Full Text] [Related]
4. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of rituximab in kidney allotransplantation.
Genberg H; Hansson A; Wernerson A; Wennberg L; Tydén G
Am J Transplant; 2006 Oct; 6(10):2418-28. PubMed ID: 16925569
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in pediatric renal transplantation: a treatment for allograft rejection with B-cell infiltrates?
Zand MS
Am J Transplant; 2008 Dec; 8(12):2489-90. PubMed ID: 19032220
[No Abstract] [Full Text] [Related]
7. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation.
Tydén G; Genberg H; Tollemar J; Ekberg H; Persson NH; Tufveson G; Wadström J; Gäbel M; Mjörnstedt L
Transplantation; 2009 May; 87(9):1325-9. PubMed ID: 19424032
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy for acute humoral rejection after kidney transplantation.
Faguer S; Kamar N; Guilbeaud-Frugier C; Fort M; Modesto A; Mari A; Ribes D; Cointault O; Lavayssière L; Guitard J; Durand D; Rostaing L
Transplantation; 2007 May; 83(9):1277-80. PubMed ID: 17496547
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in highly sensitized kidney transplant recipients.
Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
[TBL] [Abstract][Full Text] [Related]
11. Refractory CD20 Positive Cellular Rejection in Living Kidney Transplant: A Case Report and Review of Literature.
Akl AI; Sheashaa HA; Rahim MA; El Hadedy MA; Refaie AF
Exp Clin Transplant; 2019 Dec; 17(6):823-827. PubMed ID: 29534659
[TBL] [Abstract][Full Text] [Related]
12. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys.
Kelishadi SS; Azimzadeh AM; Zhang T; Stoddard T; Welty E; Avon C; Higuchi M; Laaris A; Cheng XF; McMahon C; Pierson RN
J Clin Invest; 2010 Apr; 120(4):1275-84. PubMed ID: 20335656
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial.
Schiffer L; Schiffer M; Merkel S; Schwarz A; Mengel M; Jürgens C; Schroeder C; Zoerner AA; Püllmann K; Bröcker V; Becker JU; Dämmrich ME; Träder J; Grosshennig A; Biertz F; Haller H; Koch A; Gwinner W
Trials; 2012 Oct; 13():199. PubMed ID: 23101480
[TBL] [Abstract][Full Text] [Related]
14. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
[TBL] [Abstract][Full Text] [Related]
15. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report.
Aranda JM; Scornik JC; Normann SJ; Lottenberg R; Schofield RS; Pauly DF; Miles M; Hill JA; Sleasman JW; Skoda-Smith S
Transplantation; 2002 Mar; 73(6):907-10. PubMed ID: 11923690
[TBL] [Abstract][Full Text] [Related]
17. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.
Steinmetz OM; Lange-Hüsken F; Turner JE; Vernauer A; Helmchen U; Stahl RA; Thaiss F; Panzer U
Transplantation; 2007 Oct; 84(7):842-50. PubMed ID: 17984836
[TBL] [Abstract][Full Text] [Related]
18. Treatment of vascular rejection with rituximab in cardiac transplantation.
Garrett HE; Duvall-Seaman D; Helsley B; Groshart K
J Heart Lung Transplant; 2005 Sep; 24(9):1337-42. PubMed ID: 16143254
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
20. New treatments for acute humoral rejection of kidney allografts.
Venetz JP; Pascual M
Expert Opin Investig Drugs; 2007 May; 16(5):625-33. PubMed ID: 17461736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]